首页> 外文期刊>British journal of ophthalmology >Effects of topical nipradilol, a beta blocking agent with alpha blocking and nitroglycerin-like activities, on intraocular pressure and aqueous dynamics in humans.
【24h】

Effects of topical nipradilol, a beta blocking agent with alpha blocking and nitroglycerin-like activities, on intraocular pressure and aqueous dynamics in humans.

机译:局部尼帕地洛(一种具有α阻断和类似硝酸甘油活性的β阻断剂)对人眼压和水动力学的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

AIMS: To study the effects of topical nipradilol, a non-selective beta blocker with alpha blocking and nitroglycerin-like activities, on intraocular pressure (IOP) and aqueous humour dynamics in normal humans and in patients with ocular hypertension. METHODS: Nipradilol (0.06%, 0.125%, 0.25%, 0.5%) was applied to normal volunteers (n = 12) to test for IOP lowering effects. In a second group of normal volunteers (n = 11), nipradilol (0.125% and 0.25%) and timolol (0. 5%) were compared for IOP lowering effects. After a single administration of 0.25% nipradilol, IOP, flare intensity in the anterior chamber, aqueous flow, uveoscleral outflow, tonographic outflow facility, and episcleral venous pressure were either directly measured or mathematically calculated. Topical nipradilol (0.25%) was administered to 24 patients with ocular hypertension twice daily for 8 weeks. RESULTS: Administration of 0.25% nipradilol decreased IOP with a maximum reduction of 4.2 mm Hg lasting 12 hours. A single instillation of both 0.25% nipradilol and 0.5% timolol reduced the IOP in normotensive human subjects to the same degree. A single instillation of 0.25% nipradilol decreased the aqueous flow rate in the treated eye by 20%. Nipradilol produced no significant effect in tonographic outflow facility or episcleral venous pressure, but uveoscleral outflow was increased. In patients with ocular hypertension, twice daily instillation of 0.25% nipradilol decreased IOP without tachyphylaxis for the 8 week test period. CONCLUSION: Topical nipradilol (0.25%) reduced IOP by decreasing the aqueous flow rate and probably also by increasing uveoscleral outflow. Nipradilol should be further investigated as a new antiglaucoma drug.
机译:目的:研究局部尼帕地洛(一种具有α阻断和类似硝酸甘油活性的非选择性β受体阻滞剂)对正常人和高眼压患者眼内压(IOP)和房水动力学的影响。方法:将尼帕地洛(0.06%,0.125%,0.25%,0.5%)施用于正常志愿者(n = 12)以测试降低眼压的效果。在第二组正常志愿者(n = 11)中,比较了尼帕地洛(0.125%和0.25%)和噻吗洛尔(0.5%)的降低眼压的作用。一次施用0.25%的尼泊地洛尔,眼压,前房的耀斑强度,水流,葡萄膜巩膜流出,眼底成像流出设施和巩膜静脉压可直接测量或通过数学计算。 24例高眼压症患者每天两次局部用尼普地洛(0.25%),共8周。结果:给予0.25%的尼地洛尔降低了眼压,最大降低了4.2 mm Hg,持续了12小时。一次滴入0.25%的尼地洛尔和0.5%的噻吗洛尔,可使血压正常的人的IOP降低相同程度。一次滴注0.25%的nipradilol可将治疗眼中的水性流速降低20%。 Nipradilol对眼底成像流出设施或巩膜静脉压没有明显影响,但葡萄膜巩膜流出增加。在高眼压患者中,在8周的测试期间,每天两次滴注0.25%的nipradilol可以降低IOP而无速激肽。结论:局部尼普地洛(0.25%)可通过降低房水流速和可能通过增加葡萄膜巩膜流出而降低眼压。尼帕地洛作为一种新的抗青光眼药物应作进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号